Market Cap 25.25B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 10.28
Forward PE 11.56
Profit Margin 16.87%
Debt to Equity Ratio 0.35
Volume 14,994,699
Avg Vol 2,118,414
Day's Range N/A - N/A
Shares Out 146.70M
Stochastic %K 46%
Beta 0.13
Analysts Sell
Price Target $179.78

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
jedrzejjj10
jedrzejjj10 Dec. 20 at 10:06 AM
$BIIB In my opinion, this isn't the end of the growth. I'm holding the shares. Now is not the time to sell. GLTA
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 19 at 4:12 PM
Enter: $BIIB Calls Strike Price: $172 Expiry Date: JAN 09 2026 Buy in Price: $4.37 - $5.00 Sell Price: $6.21 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:53 PM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $169.91, showing a potential reversal opportunity given the RSI at 30.78, indicating oversold conditions. The stock is currently trading below both the 30-day MA (172.04) and the 50-day MA (162.45), suggesting bearish momentum, but the low RSI signals a potential bounce. Directional Bias: Given the oversold RSI and proximity to the 60D low (135.39), there is a bullish bias for a short-term reversal. The ATR of 5.29 indicates moderate volatility, allowing for reasonable price movements. Trade Plan: - Suggested Entry: $170.50 (slightly above the last close) - Stop Loss: $165.00 (below recent support) - Take Profit Targets: 1. $175.00 (2.9% gain) 2. $180.00 (5.9% gain) 3. $199.00 (17% gain) This setup allows for a favorable risk-reward ratio while targeting a significant upside based on current metrics. Monitor closely for price action around targets. https://privateprofiteers.com
0 · Reply
ShadowBanningIsBad
ShadowBanningIsBad Dec. 19 at 3:15 PM
$BIIB Hate to break it to you but 2025 earings were less than 2024 and 2026 will be less then 2025 and 2027 will be less than 2026. Why are you guys paying more for a company who will make less and less every year going forward?
1 · Reply
dogDazeSummer
dogDazeSummer Dec. 18 at 5:07 PM
$IFRX Watch for double bottom formation (early vs mid December) amid tax loss selling. They’ve tried to take below on 2 occasions, both unsuccessful thus far. Coming off a catalyst rich 2025, we now have a de-risked asset with Izicopan that works in CSU & HS. If you think BP cares about ‘time to revenue’ more than a SAFE / ORAL ‘revenue generator’, you might be mistaken. An easy double from current prices after retail throws in the towel, amid obvious & expected exhaustion (given time). $JPM biggest annual event & good to see the company continue to focus on partnerships, funding, BD, how quickly we forget $BIIB $AMGN like the space and paid 10-50x to be in it. Their respective buys are pre clinical and the latter has liver tox side effects. #See5 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 18 at 3:46 PM
Enter: $BIIB Calls Strike Price: $175 Expiry Date: JAN 09 2026 Buy in Price: $4.31 - $4.90 Sell Price: $9.78 Profit : +127% (Turn every $1 into $2.27) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Quantumup
Quantumup Dec. 17 at 10:00 PM
Raymond James🏁 $LXEO Strong Buy/$25 $LRMR $BIIB $RCKT $TNYA Raymond James said in its note: Initiating coverage of Lexeo Therapeutics (LXEO) with a Strong Buy rating and $25 price target, as we think Lexeo's lead asset LX2006 (AAV gene therapy for cardiomyopathy associated with Friedreich's Ataxia) is well-positioned for success in its pivotal trial, based on strong results from two Phase 1/2 clinical trials and constructive feedback from FDA. While pivotal data from this program is not anticipated until 1H27, we anticipate the stock will move next year on a finalized pivotal protocol with FDA and initial POC data on a second, unmodeled gene therapy asset - LX2020 for PKP2-ACM. We model LX2006 revenue of $14.1M, $107.1M, $255.5M, $418.1M, $599.3M and $805.3M for FY27-32, respectively. Assigning an 11x forward EV/revenue multiple to our FY32 revenue estimate of $805.3M, discounted back at an annual 20% discount rate, we derive a price target of $25.
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:40 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB is currently trading at $171.57, showing a potential for upward movement given its recent low RSI of 32.08, indicating oversold conditions. The stock is also positioned above its 30-day moving average (MA30) of 170.73, suggesting a bullish sentiment may be developing. Directional Bias: The RSI indicates that the stock is oversold, while the price is near the 60D low of 135.39, providing a favorable risk-reward scenario for a bounce back. The MA50 at 161.67 supports this bullish outlook. Trade Plan: - Suggested Entry: $172.00 - Stop Loss: $165.00 (4.5% risk) - Take Profit Targets: 1. $180.00 (4.7% gain) 2. $185.00 (7.8% gain) 3. $200.00 (16.6% gain) With these targets, the third take profit offers a potential ROI of over 17%. Monitor price action closely for optimal entry. https://privateprofiteers.com
0 · Reply
Est1er_Holmes
Est1er_Holmes Dec. 16 at 4:35 PM
$BIIB SBFM cash-heavy balance + growing top line… that’s not typical microcap
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 16 at 2:48 PM
Enter: $BIIB Calls Strike Price: $175 Expiry Date: JAN 09 2026 Buy in Price: $5.50 - $5.60 Sell Price: $8.74 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Latest News on BIIB
AI Stocks Are Taking a Beating. What to Buy Instead.

Nov 21, 2025, 1:13 PM EST - 4 weeks ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY


Biogen Completes Acquisition of Alcyone Therapeutics

Nov 14, 2025, 4:05 PM EST - 5 weeks ago

Biogen Completes Acquisition of Alcyone Therapeutics

IONS


Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 9:16 PM EDT - 7 weeks ago

Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript


Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 9, 2025, 10:54 AM EDT - 2 months ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again


BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 3, 2025, 8:50 AM EDT - 2 months ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?


jedrzejjj10
jedrzejjj10 Dec. 20 at 10:06 AM
$BIIB In my opinion, this isn't the end of the growth. I'm holding the shares. Now is not the time to sell. GLTA
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 19 at 4:12 PM
Enter: $BIIB Calls Strike Price: $172 Expiry Date: JAN 09 2026 Buy in Price: $4.37 - $5.00 Sell Price: $6.21 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:53 PM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $169.91, showing a potential reversal opportunity given the RSI at 30.78, indicating oversold conditions. The stock is currently trading below both the 30-day MA (172.04) and the 50-day MA (162.45), suggesting bearish momentum, but the low RSI signals a potential bounce. Directional Bias: Given the oversold RSI and proximity to the 60D low (135.39), there is a bullish bias for a short-term reversal. The ATR of 5.29 indicates moderate volatility, allowing for reasonable price movements. Trade Plan: - Suggested Entry: $170.50 (slightly above the last close) - Stop Loss: $165.00 (below recent support) - Take Profit Targets: 1. $175.00 (2.9% gain) 2. $180.00 (5.9% gain) 3. $199.00 (17% gain) This setup allows for a favorable risk-reward ratio while targeting a significant upside based on current metrics. Monitor closely for price action around targets. https://privateprofiteers.com
0 · Reply
ShadowBanningIsBad
ShadowBanningIsBad Dec. 19 at 3:15 PM
$BIIB Hate to break it to you but 2025 earings were less than 2024 and 2026 will be less then 2025 and 2027 will be less than 2026. Why are you guys paying more for a company who will make less and less every year going forward?
1 · Reply
dogDazeSummer
dogDazeSummer Dec. 18 at 5:07 PM
$IFRX Watch for double bottom formation (early vs mid December) amid tax loss selling. They’ve tried to take below on 2 occasions, both unsuccessful thus far. Coming off a catalyst rich 2025, we now have a de-risked asset with Izicopan that works in CSU & HS. If you think BP cares about ‘time to revenue’ more than a SAFE / ORAL ‘revenue generator’, you might be mistaken. An easy double from current prices after retail throws in the towel, amid obvious & expected exhaustion (given time). $JPM biggest annual event & good to see the company continue to focus on partnerships, funding, BD, how quickly we forget $BIIB $AMGN like the space and paid 10-50x to be in it. Their respective buys are pre clinical and the latter has liver tox side effects. #See5 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 18 at 3:46 PM
Enter: $BIIB Calls Strike Price: $175 Expiry Date: JAN 09 2026 Buy in Price: $4.31 - $4.90 Sell Price: $9.78 Profit : +127% (Turn every $1 into $2.27) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Quantumup
Quantumup Dec. 17 at 10:00 PM
Raymond James🏁 $LXEO Strong Buy/$25 $LRMR $BIIB $RCKT $TNYA Raymond James said in its note: Initiating coverage of Lexeo Therapeutics (LXEO) with a Strong Buy rating and $25 price target, as we think Lexeo's lead asset LX2006 (AAV gene therapy for cardiomyopathy associated with Friedreich's Ataxia) is well-positioned for success in its pivotal trial, based on strong results from two Phase 1/2 clinical trials and constructive feedback from FDA. While pivotal data from this program is not anticipated until 1H27, we anticipate the stock will move next year on a finalized pivotal protocol with FDA and initial POC data on a second, unmodeled gene therapy asset - LX2020 for PKP2-ACM. We model LX2006 revenue of $14.1M, $107.1M, $255.5M, $418.1M, $599.3M and $805.3M for FY27-32, respectively. Assigning an 11x forward EV/revenue multiple to our FY32 revenue estimate of $805.3M, discounted back at an annual 20% discount rate, we derive a price target of $25.
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:40 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB is currently trading at $171.57, showing a potential for upward movement given its recent low RSI of 32.08, indicating oversold conditions. The stock is also positioned above its 30-day moving average (MA30) of 170.73, suggesting a bullish sentiment may be developing. Directional Bias: The RSI indicates that the stock is oversold, while the price is near the 60D low of 135.39, providing a favorable risk-reward scenario for a bounce back. The MA50 at 161.67 supports this bullish outlook. Trade Plan: - Suggested Entry: $172.00 - Stop Loss: $165.00 (4.5% risk) - Take Profit Targets: 1. $180.00 (4.7% gain) 2. $185.00 (7.8% gain) 3. $200.00 (16.6% gain) With these targets, the third take profit offers a potential ROI of over 17%. Monitor price action closely for optimal entry. https://privateprofiteers.com
0 · Reply
Est1er_Holmes
Est1er_Holmes Dec. 16 at 4:35 PM
$BIIB SBFM cash-heavy balance + growing top line… that’s not typical microcap
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 16 at 2:48 PM
Enter: $BIIB Calls Strike Price: $175 Expiry Date: JAN 09 2026 Buy in Price: $5.50 - $5.60 Sell Price: $8.74 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Quantumup
Quantumup Dec. 16 at 2:04 PM
H.C. Wainwright⬆️ $STOK's PT to $50 from $35 and reiterated at Buy $BIIB $UCBJY UCBJF $JAZZ $PRAX H.C. Wainwright said—Zorevunersen's rigorous propensity-weighted analysis reveals a clinically transformative ~82% seizure reduction and significant cognitive gains, substantially de-risking the Phase 3 EMPEROR study which is powered for far more modest improvements. With strong KOL validation supporting its use in severe patients despite safety signals, and new data expanding the addressable market to "Atypical Dravet," Stoke offers a scientifically validated "root cause" opportunity with significant regulatory upside. Therefore, given the data, the potential of zorevunersen for atypical Dravet patients, and the KOL validation, we revisited our PoS assumptions, and our penetration assumptions, which increases our PT from $35 to $50.
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 16 at 2:02 PM
$IFRX this little piggy going to market to by .97 x 9900 x? Premakrt. Let’s see how big sellers are. If $BIIB paid $100M + $900M “bio bucks” - I’m ok w $80M total. NFA!
0 · Reply
howardlindzon
howardlindzon Dec. 16 at 3:08 AM
$LULU $TTD and $BIIB out of the $QQQ ... Interesting
3 · Reply
RunnerSignals
RunnerSignals Dec. 15 at 9:33 PM
Dip-to-Rip! $KO $BIIB $AVXL $FGNX $AIRS started shaky but bounced hard today good job!
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:13 AM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $174.1, positioned within a range defined by a 60D High of $185.17 and a 60D Low of $135.39. The current RSI of 47.99 indicates neutral momentum, suggesting potential for upward movement as it approaches oversold territory. Directional Bias: Given the proximity to the MA30 (169.35) and the MA50 (161.0), there is a bullish bias as the price is above both moving averages, indicating a potential upward trend. The ATR of 5.4 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $175.00 - Stop Loss: $168.00 (4.5% risk) - Take Profit Targets: 1. $180.00 (2.86% ROI) 2. $185.00 (5.69% ROI) 3. $204.00 (17.19% ROI) This plan provides a structured approach to capitalize on potential upward momentum while managing risk effectively. https://privateprofiteers.com
0 · Reply
dogDazeSummer
dogDazeSummer Dec. 14 at 6:27 PM
$IFRX $MLTX $INCY $BIIB https://www.dermatologytimes.com/view/global-hidradenitis-suppurativa-atlas-ghisa-finds-hs-affects-1-of-the-world-s-population?utm_content=361519958&utm_medium=social&utm_source=twitter&hss_channel=tw-55642575 “Our analysis confirms that HS affects far more people than previously thought, and this has profound implications for awareness, screening, and resource allocation,” she said.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 14 at 4:15 PM
Enter: $BIIB Calls Strike Price: $190 Expiry Date: JAN 09 2026 Buy in Price: $1.08 - $2.90 Sell Price: $2.31 Profit : +114% (Turn every $1 into $2.14) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 13 at 11:21 PM
$BIIB Biogen Inc. has spent decades focusing on diseases of the brain and spinal cord, building scientific platforms that target protein aggregation, RNA splicing, and neurodegeneration. https://biotechhealthx.com/biotech-news/how-biogen-inc-biib-built-one-of-biotechs-most-specialized-neuroscience-platforms/
0 · Reply
RunnerSignals
RunnerSignals Dec. 13 at 9:01 PM
Behind the Paywall Some pullbacks whisper, others set traps. $OVV $GOOG $BIIB $MNST $KO are dipping but still trending up. full breakdown and best near-term setup inside for pro subscribers only https://stocksrunner.com/news/2025-12-13-stocks-ready-to-bounce-back-after-pullbacks
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 5:07 PM
Morgan Stanley has adjusted their stance on Biogen ( $BIIB ), setting the rating to Equal-Weight with a target price of 149 → 156.
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 12 at 2:18 PM
Enter: $BIIB Calls Strike Price: $180 Expiry Date: JAN 02 2026 Buy in Price: $2.21 - $5.30 Sell Price: $4.57 Profit : +107% (Turn every $1 into $2.07) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:07 PM
Actionable Trade Alert for $BIIB: Market Context: $BIIB closed at $179.09, showing strength but nearing overbought territory with an RSI of 67.12. The stock is above both the 30-day MA (168.75) and 50-day MA (160.76), indicating bullish momentum. The 60-day high of $185.17 presents a key resistance level, while the low of $135.39 offers support. Directional Bias: The bullish trend is supported by the stock's position above the moving averages, but caution is warranted due to the RSI approaching overbought levels. Trade Plan: - Suggested Entry: $179.50 - Stop Loss: $173.00 (3.5% risk) - Take Profit Targets: 1. $185.00 (3.3% gain) 2. $190.00 (5.9% gain) 3. $210.00 (17.3% gain) This plan offers a potential ROI of over 17% on the third target while maintaining a reasonable risk-reward ratio. Monitor the stock closely for volatility as indicated by the ATR of 5.49. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply